BEAM - Beam Therapeutics Inc - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

1.612B

Cash

1.095B

Avg Qtr Burn

-34.78M

Short % of Float

16.48%

Insider Ownership

1.45%

Institutional Own.

91.00%

Qtr Updated

03/31/24

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
BEAM-101 Details Beta thalessemia, Sickle cell disease	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
BEAM-201 Details T-cell lymphoma, Blood cancer, Cancer, Acute lymphoblastic leukemia	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
BEAM-302 Details Alpha-1 Antitrypsin Deficiency	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.